Engineered Yeast: Revolutionary Colorectal Cancer Immunotherapy Breakthrough

Title: Engineered Yeast Shows Promise in Colorectal Cancer Treatment

Introduction
Saccharomyces cerevisiae var. boulardii is a type of yeast being used to treat colorectal cancer. Researchers at Washington University in St. Louis developed a method to use this yeast to deliver immune checkpoint inhibitors to gastrointestinal tumors in mice.

Research Background

Previous studies focused on Escherichia coli bacteria that can produce immune checkpoint inhibitors when injected into tumors. This new study explores how S. cerevisiae var. boulardii, also known as S. boulardii, can be ingested and used to target tumors.

Mechanism of Action

The research team inserted plasmids into the yeast. These plasmids contain instructions to create small antibody variants that block PD-1. PD-1 is a protein on T cells that helps cancer cells evade the immune system. Blocking this protein allows T cells to attack and destroy tumors.

Study Results

Mice with colorectal cancer that consumed the engineered yeast showed fewer tumors compared to untreated mice and those receiving traditional immunotherapy. The researchers believe that both the immune checkpoint inhibitors and the properties of S. boulardii play a role in reducing tumors.

Expert Opinion

Morten Sommer, a microbiologist not involved in the study, praised its execution. He noted that this research demonstrates the potential of S. boulardii to deliver immune checkpoint inhibitors.

Conclusion

This study highlights a promising approach in cancer treatment. The engineered yeast may offer a new method to enhance the immune response against colorectal cancer.